Literature DB >> 8836967

Proteasome inhibition enhances the stability of mouse Cu/Zn superoxide dismutase with mutations linked to familial amyotrophic lateral sclerosis.

E K Hoffman1, H M Wilcox, R W Scott, R Siman.   

Abstract

Point mutations occurring within the Cu/Zn superoxide dismutase (SOD1) gene have been implicated in the etiology of some cases of familial amyotrophic lateral sclerosis (FALS). In order to better understand the functional consequences of these mutations, we have introduced FALS mutations into the mouse SOD1 gene and studied the expression of the mutant templates in stably transformed cell lines. Pulse-chase analyses of lysates derived from cell lines stably expressing the Cu/Zn SOD isoforms indicate that the FALS mutant Cu/Zn SOD proteins are turned over more rapidly than wild-type SOD. Protease inhibitors specific for the major intracellular proteolytic activities were used to characterize the degradative pathways involved in the turnover of mutant Cu/Zn SOD. Inhibition of the chymotrypsin-like activity of the proteasome (also known as multicatalytic proteinase or ubiquitin, ATP-dependent proteinase) by a synthetic dipeptide aldehyde led to a significant increase in levels of the mutant Cu/Zn SOD implicating this proteolytic pathway in the turnover of the FALS mutant SOD proteins.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8836967

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  28 in total

1.  Dorfin localizes to the ubiquitylated inclusions in Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and amyotrophic lateral sclerosis.

Authors:  Nozomi Hishikawa; Jun-Ichi Niwa; Manabu Doyu; Takashi Ito; Shinsuke Ishigaki; Yoshio Hashizume; Gen Sobue
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

Review 2.  Roles for the ubiquitin-proteasome pathway in protein quality control and signaling in the retina: implications in the pathogenesis of age-related macular degeneration.

Authors:  Fu Shang; Allen Taylor
Journal:  Mol Aspects Med       Date:  2012-04-10

3.  Proteasome inhibitor MG-132 induces C6 glioma cell apoptosis via oxidative stress.

Authors:  Wen-hai Fan; Yi Hou; Fan-kai Meng; Xiao-fei Wang; Yi-nan Luo; Peng-fei Ge
Journal:  Acta Pharmacol Sin       Date:  2011-04-18       Impact factor: 6.150

4.  The triage of damaged proteins: degradation by the ubiquitin-proteasome pathway or repair by molecular chaperones.

Authors:  Carla Marques; Weimin Guo; Paulo Pereira; Allen Taylor; Cam Patterson; Paul C Evans; Fu Shang
Journal:  FASEB J       Date:  2006-02-09       Impact factor: 5.191

5.  Effect of CCS on the accumulation of FALS SOD1 mutant-containing aggregates and on mitochondrial translocation of SOD1 mutants: implication of a free radical hypothesis.

Authors:  Ha Kun Kim; Youn Wook Chung; P Boon Chock; Moon B Yim
Journal:  Arch Biochem Biophys       Date:  2011-02-24       Impact factor: 4.013

Review 6.  Biochemical properties of insect and crustacean proteasomes.

Authors:  D L Mykles
Journal:  Mol Biol Rep       Date:  1997-03       Impact factor: 2.316

Review 7.  Role of ubiquitin-proteasome-mediated proteolysis in nervous system disease.

Authors:  Ashok N Hegde; Sudarshan C Upadhya
Journal:  Biochim Biophys Acta       Date:  2010-08-03

8.  Composition of soluble misfolded superoxide dismutase-1 in murine models of amyotrophic lateral sclerosis.

Authors:  Per Zetterström; Karin S Graffmo; Peter M Andersen; Thomas Brännström; Stefan L Marklund
Journal:  Neuromolecular Med       Date:  2012-10-18       Impact factor: 3.843

9.  Cytosolic superoxide dismutase (SOD1) is critical for tolerating the oxidative stress of zinc deficiency in yeast.

Authors:  Chang-Yi Wu; Janet Steffen; David J Eide
Journal:  PLoS One       Date:  2009-09-16       Impact factor: 3.240

Review 10.  Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond.

Authors:  Hristelina Ilieva; Magdalini Polymenidou; Don W Cleveland
Journal:  J Cell Biol       Date:  2009-12-14       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.